

# Roland R Griffiths

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/88935/publications.pdf>

Version: 2024-02-01

105  
papers

11,829  
citations

38742

50  
h-index

31849

101  
g-index

110  
all docs

110  
docs citations

110  
times ranked

4197  
citing authors

#	ARTICLE	IF	CITATIONS
1	Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 1181-1197.	4.0	1,221
2	Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 481.	11.0	648
3	Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. <i>Psychopharmacology</i> , 2011, 218, 649-665.	3.1	638
4	Pilot study of the 5-HT <sub>2A</sub> agonist psilocybin in the treatment of tobacco addiction. <i>Journal of Psychopharmacology</i> , 2014, 28, 983-992.	4.0	613
5	A critical review of caffeine withdrawal: empirical validation of symptoms and signs, incidence, severity, and associated features. <i>Psychopharmacology</i> , 2004, 176, 1-29.	3.1	438
6	Long-term follow-up of psilocybin-facilitated smoking cessation. <i>American Journal of Drug and Alcohol Abuse</i> , 2017, 43, 55-60.	2.1	430
7	An automated version of the digit symbol substitution test (DSST). <i>Behavior Research Methods</i> , 1982, 14, 463-466.	4.0	325
8	Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin. <i>Journal of Psychopharmacology</i> , 2015, 29, 1182-1190.	4.0	318
9	Psilocybin-Occasioned Mystical Experiences in the Treatment of Tobacco Addiction. <i>Current Drug Abuse Reviews</i> , 2015, 7, 157-164.	3.4	306
10	Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. <i>Journal of Psychopharmacology</i> , 2016, 30, 1268-1278.	4.0	303
11	Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. , 2019, 197, 83-102.		296
12	Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. <i>Journal of Psychopharmacology</i> , 2018, 32, 49-69.	4.0	285
13	Factor Analysis of the Mystical Experience Questionnaire: A Study of Experiences Occasioned by the Hallucinogen Psilocybin. <i>Journal for the Scientific Study of Religion</i> , 2012, 51, 721-737.	1.5	243
14	Benzodiazepine self-administration in humans and laboratory animals - implications for problems of long-term use and abuse. <i>Psychopharmacology</i> , 1997, 134, 1-37.	3.1	238
15	The Subjective Effects of Psychedelics Are Necessary for Their Enduring Therapeutic Effects. <i>ACS Pharmacology and Translational Science</i> , 2021, 4, 568-572.	4.9	223
16	The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act. <i>Neuropharmacology</i> , 2018, 142, 143-166.	4.1	184
17	Potential Therapeutic Effects of Psilocybin. <i>Neurotherapeutics</i> , 2017, 14, 734-740.	4.4	180
18	The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. <i>Journal of Psychopharmacology</i> , 2016, 30, 1279-1295.	4.0	175

#	ARTICLE	IF	CITATIONS
19	Principles of initial experimental drug abuse liability assessment in humans. <i>Drug and Alcohol Dependence</i> , 2003, 70, S41-S54.	3.2	174
20	Principles of laboratory assessment of drug abuse liability and implications for clinical development. <i>Drug and Alcohol Dependence</i> , 2009, 105, S14-S25.	3.2	174
21	Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety. <i>Journal of Contextual Behavioral Science</i> , 2020, 15, 39-45.	2.6	172
22	Emotions and brain function are altered up to one month after a single high dose of psilocybin. <i>Scientific Reports</i> , 2020, 10, 2214.	3.3	169
23	Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up. <i>Journal of Psychopharmacology</i> , 2022, 36, 151-158.	4.0	162
24	Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 36, 393-430.	1.7	152
25	Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. <i>Journal of Psychopharmacology</i> , 2018, 32, 756-769.	4.0	152
26	Cessation and reduction in alcohol consumption and misuse after psychedelic use. <i>Journal of Psychopharmacology</i> , 2019, 33, 1088-1101.	4.0	145
27	Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT. <i>PLoS ONE</i> , 2019, 14, e0214377.	2.5	132
28	Effects of mecamylamine on human cigarette smoking and subjective ratings. <i>Psychopharmacology</i> , 1986, 88, 420-5.	3.1	128
29	Opioids: Similarity between evaluations of subjective effects and animal self-administration results. <i>Clinical Pharmacology and Therapeutics</i> , 1979, 25, 611-617.	4.7	118
30	Psilocybin therapy increases cognitive and neural flexibility in patients with major depressive disorder. <i>Translational Psychiatry</i> , 2021, 11, 574.	4.8	115
31	Caffeine Use Disorder: A Comprehensive Review and Research Agenda. <i>Journal of Caffeine Research</i> , 2013, 3, 114-130.	0.9	101
32	Kratom ( <i>Mitragyna speciosa</i> ): User demographics, use patterns, and implications for the opioid epidemic. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107849.	3.2	98
33	Self-injection of barbiturates, benzodiazepines and other sedative-anxiolytics in baboons. <i>Psychopharmacology</i> , 1991, 103, 154-161.	3.1	96
34	Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. <i>NeuroImage</i> , 2020, 218, 116980.	4.2	92
35	5-methoxy- <i>N,N</i> -dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. <i>American Journal of Drug and Alcohol Abuse</i> , 2019, 45, 161-169.	2.1	91
36	Models of psychedelic drug action: modulation of cortical-subcortical circuits. <i>Brain</i> , 2022, 145, 441-456.	7.6	82

#	ARTICLE	IF	CITATIONS
37	Effects of caffeine on cigarette smoking and subjective response. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 34, 612-622.	4.7	81
38	Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD. <i>Journal of Psychopharmacology</i> , 2021, 35, 437-446.	4.0	79
39	Naloxone does not affect cigarette smoking. <i>Psychopharmacology</i> , 1986, 89, 261-4.	3.1	78
40	Persisting Reductions in Cannabis, Opioid, and Stimulant Misuse After Naturalistic Psychedelic Use: An Online Survey. <i>Frontiers in Psychiatry</i> , 2019, 10, 955.	2.6	75
41	High doses of dextromethorphan, an NMDA antagonist, produce effects similar to classic hallucinogens. <i>Psychopharmacology</i> , 2012, 223, 1-15.	3.1	73
42	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. <i>Psychopharmacology</i> , 2018, 235, 521-534.	3.1	73
43	An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. <i>Journal of Psychopharmacology</i> , 2017, 31, 841-850.	4.0	72
44	Diazepam and methadone interactions in methadone maintenance. <i>Clinical Pharmacology and Therapeutics</i> , 1984, 36, 534-541.	4.7	70
45	Caffeine withdrawal, acute effects, tolerance, and absence of net beneficial effects of chronic administration: cerebral blood flow velocity, quantitative EEG, and subjective effects. <i>Psychopharmacology</i> , 2009, 204, 573-585.	3.1	70
46	REINFORCING EFFECTS OF CAFFEINE IN COFFEE AND CAPSULES. <i>Journal of the Experimental Analysis of Behavior</i> , 1989, 52, 127-140.	1.1	67
47	LOW-DOSE CAFFEINE DISCRIMINATION AND SELF-REPORTED MOOD EFFECTS IN NORMAL VOLUNTEERS. <i>Journal of the Experimental Analysis of Behavior</i> , 1992, 57, 91-107.	1.1	65
48	Triazolam and zolpidem: effects on human memory and attentional processes. <i>Psychopharmacology</i> , 1999, 144, 8-19.	3.1	64
49	Survey of entity encounter experiences occasioned by inhaled <i>N,N</i> -dimethyltryptamine: Phenomenology, interpretation, and enduring effects. <i>Journal of Psychopharmacology</i> , 2020, 34, 1008-1020.	4.0	64
50	Psilocybin, psychological distress, and suicidality. <i>Journal of Psychopharmacology</i> , 2015, 29, 1041-1043.	4.0	62
51	Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. <i>Journal of Clinical Psychiatry</i> , 2005, 66 Suppl 9, 31-41.	2.2	62
52	Alprazolam absorption kinetics affects abuse liability*. <i>Clinical Pharmacology and Therapeutics</i> , 1995, 57, 356-365.	4.7	60
53	Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: effects on cognition. <i>Psychopharmacology</i> , 2018, 235, 2915-2927.	3.1	58
54	Recent Progress in Lyme Disease and Remaining Challenges. <i>Frontiers in Medicine</i> , 2021, 8, 666554.	2.6	55

#	ARTICLE	IF	CITATIONS
55	Neuroticism is associated with challenging experiences with psilocybin mushrooms. <i>Personality and Individual Differences</i> , 2017, 117, 155-160.	2.9	54
56	Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. <i>Frontiers in Psychology</i> , 2018, 9, 2459.	2.1	54
57	Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches. <i>Journal of Psychopharmacology</i> , 2021, 35, 353-361.	4.0	49
58	The adenosine receptor antagonist CGS15943 reinstates cocaine-seeking behavior and maintains self-administration in baboons. <i>Psychopharmacology</i> , 2003, 168, 155-163.	3.1	48
59	Acute effects of zolpidem extended-release on cognitive performance and sleep in healthy males after repeated nightly use.. <i>Experimental and Clinical Psychopharmacology</i> , 2012, 20, 28-39.	1.8	48
60	Asymmetrical cross-generalization in drug discrimination with lorazepam and pentobarbital training conditions. <i>Drug Development Research</i> , 1989, 16, 355-364.	2.9	47
61	Cigarette smoking and subjective response in alcoholics: Effects of pentobarbital. <i>Clinical Pharmacology and Therapeutics</i> , 1983, 33, 806-812.	4.7	46
62	HUMAN COFFEE DRINKING: MANIPULATION OF CONCENTRATION AND CAFFEINE DOSE. <i>Journal of the Experimental Analysis of Behavior</i> , 1986, 45, 133-148.	1.1	46
63	Psychedelics in Psychiatry—Keeping the Renaissance From Going Off the Rails. <i>JAMA Psychiatry</i> , 2021, 78, 469.	11.0	44
64	Physiological, subjective and reinforcing effects of oral and intravenous cocaine in humans. <i>Psychopharmacology</i> , 2001, 156, 435-444.	3.1	43
65	CHOICE BETWEEN FOOD AND HEROIN: EFFECTS OF MORPHINE, NALOXONE, AND SECOBARBITAL. <i>Journal of the Experimental Analysis of Behavior</i> , 1981, 35, 335-351.	1.1	39
66	Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance and drug self-administration. <i>Psychopharmacology</i> , 1989, 99, 309-315.	3.1	34
67	Subjective features of the psilocybin experience that may account for its self-administration by humans: a double-blind comparison of psilocybin and dextromethorphan. <i>Psychopharmacology</i> , 2020, 237, 2293-2304.	3.1	32
68	Evaluating Dependence Criteria for Caffeine. <i>Journal of Caffeine Research</i> , 2011, 1, 219-225.	0.9	31
69	Human progressive-ratio performance: Maintenance by pentobarbital. <i>Psychopharmacology</i> , 1983, 79, 4-9.	3.1	30
70	A Single Belief-Changing Psychedelic Experience Is Associated With Increased Attribution of Consciousness to Living and Non-living Entities. <i>Frontiers in Psychology</i> , 2022, 13, 852248.	2.1	30
71	Abuse liability assessment of anxiolytics/ hypnotics: rationale and laboratory lore. <i>Addiction</i> , 1991, 86, 1625-1632.	3.3	29
72	Classic Psychedelic Coadministration with Lithium, but Not Lamotrigine, is Associated with Seizures: An Analysis of Online Psychedelic Experience Reports. <i>Pharmacopsychiatry</i> , 2021, 54, 240-245.	3.3	29

#	ARTICLE	IF	CITATIONS
73	The Acute Effects of the Atypical Dissociative Hallucinogen Salvinorin A on Functional Connectivity in the Human Brain. <i>Scientific Reports</i> , 2020, 10, 16392.	3.3	28
74	Smoking behavior and tobacco smoke intake: Response of smokers to shortened cigarettes. <i>Clinical Pharmacology and Therapeutics</i> , 1982, 32, 90-97.	4.7	27
75	DISCRIMINATIVE STIMULUS EFFECTS OF DIAZEPAM AND BUSPIRONE IN NORMAL VOLUNTEERS. <i>Journal of the Experimental Analysis of Behavior</i> , 1995, 63, 277-294.	1.1	26
76	Acute effects of triazolam on false recognition. <i>Memory and Cognition</i> , 2000, 28, 1357-1365.	1.6	23
77	Effects of Triazolam on Brain Activity During Episodic Memory Encoding: A PET Study. <i>Neuropsychopharmacology</i> , 2001, 25, 744-756.	5.4	23
78	Caffeine Withdrawal and Dependence: A Convenience Survey Among Addiction Professionals. <i>Journal of Caffeine Research</i> , 2013, 3, 67-71.	0.9	22
79	Weekly Energy Drink Use Is Positively Associated with Delay Discounting and Risk Behavior in a Nationwide Sample of Young Adults. <i>Journal of Caffeine Research</i> , 2016, 6, 10-19.	0.9	22
80	Nicotine reinforcement in never-smokers. <i>Psychopharmacology</i> , 2015, 232, 4243-4252.	3.1	21
81	Psychedelics and Consciousness: Distinctions, Demarcations, and Opportunities. <i>International Journal of Neuropsychopharmacology</i> , 2021, 24, 615-623.	2.1	20
82	Phenomenology and content of the inhaled N, N-dimethyltryptamine (N, N-DMT) experience. <i>Scientific Reports</i> , 2022, 12, .	3.3	19
83	Reinforcing effects of oral cocaine: contextual determinants. <i>Psychopharmacology</i> , 2001, 154, 143-152.	3.1	18
84	Alcohol and false recognition: a dose-effect study. <i>Psychopharmacology</i> , 2001, 159, 51-57.	3.1	18
85	Acute dose-effects of scopolamine on false recognition. <i>Psychopharmacology</i> , 2001, 153, 425-433.	3.1	17
86	Stable low-rate midazolam self-injection with concurrent physical dependence under conditions of long-term continuous availability in baboons. <i>Psychopharmacology</i> , 1998, 135, 70-81.	3.1	15
87	Effects of caffeine on alcohol reinforcement: beverage choice, self-administration, and subjective ratings. <i>Psychopharmacology</i> , 2017, 234, 877-888.	3.1	14
88	Inhaled 5-methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects. <i>Journal of Psychedelic Studies</i> , 2020, 4, 114-122.	1.2	14
89	Trends in the Top-Cited Articles on Classic Psychedelics. <i>Journal of Psychoactive Drugs</i> , 2021, 53, 283-298.	1.7	13
90	Time course of pharmacokinetic and hormonal effects of inhaled high-dose salvinorin A in humans. <i>Journal of Psychopharmacology</i> , 2016, 30, 323-329.	4.0	12

#	ARTICLE	IF	CITATIONS
91	Caffeine choice prospectively predicts positive subjective effects of caffeine and d-amphetamine. <i>Drug and Alcohol Dependence</i> , 2011, 118, 341-348.	3.2	11
92	Inhaled vs. oral alprazolam: subjective, behavioral and cognitive effects, and modestly increased abuse potential. <i>Psychopharmacology</i> , 2015, 232, 871-883.	3.1	11
93	A brief manualized treatment for problematic caffeine use: A randomized control trial.. <i>Journal of Consulting and Clinical Psychology</i> , 2016, 84, 113-121.	2.0	11
94	Prevalence and Correlates of Caffeine Use Disorder Symptoms Among a United States Sample. <i>Journal of Caffeine and Adenosine Research</i> , 2020, 10, 4-11.	0.6	10
95	The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016. <i>Human Psychopharmacology</i> , 2017, 32, e2564.	1.5	9
96	The Potential of Psychedelics for End of Life and Palliative Care. <i>Current Topics in Behavioral Neurosciences</i> , 2021,, 169-184.	1.7	8
97	A randomized controlled trial of a manual-only treatment for reduction and cessation of problematic caffeine use. <i>Drug and Alcohol Dependence</i> , 2019, 195, 45-51.	3.2	7
98	Substance Abuse: Caffeine Use Disorders. , 0, , 1019-1040.		7
99	A PROCEDURE FOR STUDYING THE WITHIN-SESSION ONSET OF HUMAN DRUG DISCRIMINATION. <i>Journal of the Experimental Analysis of Behavior</i> , 1994, 61, 181-189.	1.1	6
100	LC-MS/MS quantification of salvinorin A from biological fluids. <i>Analytical Methods</i> , 2013, 5, 7042.	2.7	5
101	Human Cortical Serotonin 2A Receptor Occupancy by Psilocybin Measured Using [11C]MDL 100,907 Dynamic PET and a Resting-State fMRI-Based Brain Parcellation. <i>Frontiers in Neuroergonomics</i> , 2022, 2, .	1.1	4
102	A Critical Examination of the Caffeine Provisions in the Diagnostic and Statistical Manual, 5th Edition (DSM-5). <i>Journal of Caffeine Research</i> , 2013, 3, 101-107.	0.9	3
103	Ramelteon. <i>CNS Drugs</i> , 2005, 19, 1066-1067.	5.9	1
104	Errors in a Response Rate and in Effect Sizes in Study of Psilocybin-Assisted Therapy for Major Depressive Disorder. <i>JAMA Psychiatry</i> , 2021, 78, 569.	11.0	1
105	Amnestic effects of sodium oxybate are less than those of triazolamâ€”reply to Drs. Zvosec and Smith. <i>Psychopharmacology</i> , 2009, 207, 511-512.	3.1	0